Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, has initiated Phase II testing of its cell culture-based seasonal influenza vaccine in the US.
Subscribe to our email newsletter
This project is part of a contract awarded in 2005 by the US Department of Health and Human Services (HHS) for the development of a new cell culture- based influenza vaccine. Phase II trials involving healthy adult volunteers in the US will focus further on the safety profile and immunogenicity of the cell-based vaccine.
This vaccine was developed using the PER.C6 cell line, licensed from Dutch biotechnology company Crucell. PER.C6 Cell technology offers Sanofi Pasteur a promising and reliable production method for seasonal and pandemic influenza vaccines in addition to traditional, proven egg-based production, the company said.